Chardan Capital Decreases Earnings Estimates for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Chardan Capital dropped their FY2025 earnings estimates for shares of REGENXBIO in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company will post earnings per share of ($3.03) for the year, down from their prior forecast of ($1.39). Chardan Capital currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Chardan Capital also issued estimates for REGENXBIO’s FY2026 earnings at $4.87 EPS.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million for the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Other equities analysts have also issued reports about the stock. HC Wainwright decreased their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Leerink Partners set a $24.00 price target on REGENXBIO in a research report on Tuesday, March 18th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Raymond James started coverage on REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Morgan Stanley lifted their target price on REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $32.78.

REGENXBIO Price Performance

NASDAQ RGNX opened at $7.83 on Thursday. REGENXBIO has a 12 month low of $5.62 and a 12 month high of $21.57. The stock has a market capitalization of $392.17 million, a P/E ratio of -1.56 and a beta of 1.35. The firm’s 50-day moving average is $7.40 and its two-hundred day moving average is $8.79.

Institutional Investors Weigh In On REGENXBIO

Several large investors have recently bought and sold shares of RGNX. JPMorgan Chase & Co. boosted its stake in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock valued at $31,975,000 after buying an additional 1,659,206 shares during the period. Millennium Management LLC increased its stake in shares of REGENXBIO by 406.3% during the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after buying an additional 1,061,187 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in REGENXBIO in the fourth quarter valued at approximately $3,865,000. Norges Bank purchased a new position in REGENXBIO in the fourth quarter worth approximately $3,474,000. Finally, Cubist Systematic Strategies LLC acquired a new position in REGENXBIO during the 4th quarter worth approximately $2,793,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.